Methods

Recruitment
This study was conducted in 106 district health centers in Lima, which are marked on the map in Figure S1 . These district-based clinics provide routine health care to people living in their catchments areas and are responsible for most diagnosis and treatment of tuberculosis cases. Patients are diagnosed with pulmonary tuberculosis disease by health center clinicians on the basis of the Peru national tuberculosis guidelines which specify that individuals receive a diagnosis of pulmonary tuberculosis if at least one of two sputum smears is positive for acid-fast bacilli by Ziehl-Neelsen staining, or if a chest radiograph was consistent with tuberculosis in the absence of positive sputum smear results.
Figure S1. Study district health centers
Enrollment of index patients
On the day that a health center identified a patient with pulmonary tuberculosis, he or she was invited to participate in the study if he/she were over 16 or over and had no cognitive deficits that might interfere with giving informed consent. Once the patient consented to participate, an additional sputum sample was collected and sent for repeat sputum smear microscopy, mycobacterial culture and drug sensitivity testing as described below. We then requested permission to visit the patient's household and recruit his or her household contacts into the prospective cohort study. Study workers aimed to visit households to enroll all household members within one week of the diagnosis of the index case. The median time between index patient's diagnosis and household contact enrollment was 8 days and the interquartile range was 11 days. All individuals who lived in the same household as an index patient at the time the index patient was enrolled in the study were invited to participate. Potential participants were only excluded if they were cognitively unable to provide informed consent or assent.
Baseline assessment of index patients
At the time of the index case enrollment, study workers collected the following data through a structured questionnaire: age, gender, occupation, symptoms of tuberculosis, duration of symptoms, history of previous tuberculosis disease, alcohol, intravenous drug and tobacco history, co-morbidities including human immunodeficiency virus (HIV) status and diabetes mellitus. Patients who did not know their HIV status had blood drawn for HIV and cluster of differentiation 4 (CD4) count. Signs associated with tuberculosis disease, height and weight were recorded.
Ascertainment of tuberculosis disease Bacteriological cultures
The study staff noted results of routine sputum smear microscopy at the participating health centers. Health centers also sent sputum samples for a minority of index patients who had known risk factors for drug-resistant tuberculosis for routine culture and drugsusceptibility test (DST) at the designated public health laboratory for each center. In addition to this routine diagnostic microbiology, a sputum sample was sent to the designated research laboratory (Lima Ciudad Regional Reference Lab: September 2009 -November 2010; Blufstein Laboratorio Clínico from November 2010 to March 2012, Socios en Salud Laboratory from March to August 2012) for repeat smear, culture and drug sensitivity testing.
Sputum samples were transported in containers kept at 2-8°C and bacteriological examination was carried out as soon as possible. Samples were decontaminated and further homogenized, following the NALC method, centrifuged at 2000g to 3000g for less than 20 minutes. The resulting sediments were then neutralized in phosphate buffer solution and re-suspended. Sediments were tested for the presence of acid-fast bacilli by Ziehl-Neelsen staining and cultured by inoculation into 2 tubes containing Lowenstein-Jensen or Ogawa medium. Between March to August 2012, some specimens were also cultured using the microscopic-observation drug-susceptibility assay to allow more rapid identification of microbiologically confirmed cases. Inoculated tubes were incubated at 37°C until bacterial growth (e.g., colonies on solid media or cord formation in Microscopic Observation Drug Susceptibility Assay medium) for 60 days or until colonies were found, whichever came first. Isolates in which we observed any possible discrepancy with Mycobacterium tuberculosis complex, were assessed using biochemical identification tests. After culture, all colonies from isolates were harvested on cryovials with 7H9 Middlebrook broth with 20% of glycerol. Those were then incubated overnight at 4 Celsius degrees and stored at -60 to -80°C.
Drug-susceptibility testing
Indirect susceptibility testing to isoniazid, Rifampicin, Ethambutol and streptomycin tomycin was conducted by the Löwenstein-Jensen proportion method, using the following drug concentrations: isoniazid (0.2 and 1.0 μg/ml), rifampin (40.0 μg/ml), ethambutol (2.0 μg/ml), and streptomycin (4.0 μg/ml) and to pyrazinamide (100 ug/ml) by the Wayne method. For those isolates in which any resistance to first line drugs was detected, susceptibility testing to the following panel of second-line drugs was also performed by the agar plate method, using the following drug concentrations: kanamycin (6.0 μg/mL), capreomycin (10.0 μg/mL), ethionamide (10.0 μg/mL), ciprofloxacin (2.0 μg/mL), para-aminosalicylic acid (8.0 μg/mL), cycloserine (30.0 μg/mL).
Drug-susceptibility test results were recorded in a secure web-based information management system that is used by the laboratory and paper results were sent to the study data center for distribution to the health center, the participant, and the participant´s study file.
Quality assurance
To ensure that the results of susceptibility testing were reliable, a system of quality assurance was implemented. As an internal quality control, a standard H37Ra strain of M. tuberculosis was tested against the entire drug panel with each new batch of media. External quality control for drug-susceptibility testing was done in conjunction with the National Mycobacteria Reference Laboratory (National Institute Of Health in Peru) and The College of American Pathologist which provided panel of coded strains for blind retesting for Ziehl-Neelson smear; culture, Mycobacterium tuberculosis identification and drugs susceptibility testing for first and second line drugs. Results of yearly blind testing are presented in Appendix 1.
Tuberculosis DNA fingerprinting DNA isolates were extracted from mycobacterial colonies grown in culture media (Lowenstein-Jensen, Ogawa, or microscopic observation drug susceptibility assay) and transported from Peru to Genoscreen, France. Upon receipt, all specimens were entered into the study database by scanning of the bar-codes on the vials. The specimens were stored between -60°C to -80°C.
DNA isolation and molecular genotyping.
DNA was extracted and genotyped by 24-loci mycobacterial interspersed repetitive units-variable-number tandem repeats (MIRU-VNTR) using standard methods. 1 
Chest radiography
Chest radiographs were performed at health center or at local imaging facilities. Films were digitized in the study database, with the subject's identifying information removed, and labeled with the unique study subject identification number. Two radiologists read each film and completed a standardized form. Chest films were then given to the health center to be filed in the subject's medical chart.
Ascertainment of HIV Infection
Peru National Tuberculosis Program guidelines specify that all tuberculosis patients undergo HIV testing. From September 2009 to August 2011, HIV infection status was determined using a lab-based enzyme immunoassay (EIA), and nonnegative samples were confirmed using an immunofluorescence assay (IFA). After August 2011, a new HIV testing algorithm was employed 2 ; we first performed a rapid screening test and followed those with nonnegative tests with an EIA and a confirmatory IFA. Study staff coordinated the appropriate confirmatory tests for participants whose results were "reactive" or "indeterminate." All study participants had pre-HIV counseling by trained study staff or Ministry of Health personnel prior to the collection of a blood specimen as well as post-HIV test counseling after testing, according to the guidelines of the National STI/HIV/AIDS Program. Participants were informed of their results by a trained study worker or a trained staff member at the Ministry of Health clinic.
Follow up of Index patients
Index patients received directly observed therapy at their district health clinics as specified in the Peru National Tuberculosis Program guidelines for drug-sensitive (DS) and drug-resistant (DR) tuberculosis. Patients with drug sensitive tuberculosis received a standard 6 month course with a 2 month "intensification phase" of isoniazid, Rifampicin, Pyrazinamide and Ethambutol followed by a four month "consolidation phase" of isoniazid and Rifampicin alone. Patients with multidrug-resistant (MDR) tuberculosis received treatment according to Peru National Tuberculosis Program guidelines. Since results for routine drug resistance testing were often not available for 2-3 months after initial diagnosis, patients who were not previously suspected of having MDR tuberculosis were started on a first line drug regimen until the diagnosis of MDR was confirmed. Thus, many patients with DR tuberculosis did not start "effective therapy" until several months into their treatment course. (see definition of effective therapy below under Analyses). Study staff collected follow-up data for those with DS tuberculosis at 2, 6, 12 and 24 months and for those with DR tuberculosis again at 36 or 48 months. This included a record of all drug treatment including any changes in drug regimens and the dates when these occurred.
At two and six months, patients were evaluated by repeat sputum smear microscopy and culture. Culture positive sputum samples underwent repeat drug sensitivity testing and DNA genotyping as described above.
Enrollment of household contacts
At the time of the enrollment of household contacts, study workers collected the following data through a structured questionnaire: age, gender, relationship to index case, housing information including number of rooms, building material, type of flooring, income, education, history of incarceration, occupation, alcohol, cigarette and illicit drug intake, general health history including previous history of tuberculosis, BCG vaccination, co-morbidities including HIV and diabetes mellitus (DM), and medications taken. Participants were queried about the presence of any symptoms associated with tuberculosis disease including cough, night sweats, weight loss or fever. Participants who reported any of these symptoms were referred their local health clinic for chest radiography and clinical evaluation for active tuberculosis disease. They were also asked if they had been offered and initiated isoniazid preventive therapy.
Trained study staff measured height and weight of all participants. All household members received a tuberculin skin test, with the exception of: (1) subjects with active tuberculosis disease or a history of tuberculosis disease, (2) subjects who may have severe eczema, (3) subjects known to be hypersensitive to any component of the Tuberculin PPD RT23 Statens Serum Institut (i.e., those who tested positive in the past) and (4) subjects who previously have experienced an adverse reaction to tuberculin products. Tests were placed intradermally on the forearm and were read between 48 and 72 hours after intradermal injection. The diameter of induration was measured transversely to the long axis of the forearm and recorded in millimeters. A nurse trained in the reading of tuberculin skin test (TST) measured the diameter of the induration with a caliper to ensure the accuracy of TST.
Participants were offered HIV pretest counseling and testing. Prior to August 2011, blood samples were collected at the contacts' homes and sent to a laboratory for enzymelinked immunosorbent assay testing. Negative results were delivered to the household contacts 2-4 weeks later, while participants with non-negative results were linked to a Ministry of Health clinic for confirmatory sample extraction and follow-up. From August 2011 on, study staff performed home based HIV testing using the Determine® HIV 1/2 Ag/Ac Combo test* (Alere, Jouy-en-Josas, France).
Follow-up of household contacts
Participants were asked to advise study staff if they were diagnosed with active tuberculosis disease prior to the next scheduled study follow up visit. Participants were re-visited in their household at 2, 6 and 12 months at which times they were asked about any tuberculosis diagnoses that had occurred as well as about any symptoms of active disease. Those who reported symptoms were referred to their local health center for further clinical evaluation including a chest radiograph and sputum smear. Participants who tested negative at the initial study visit and who had not developed active tuberculosis disease at the time of the follow up visit were underwent repeat TST at 6 and 12 months.
Analyses
The time to treatment was measured as the number of days the patient reported coughing prior to diagnosis. Time to effective therapy was measured as the time from diagnosis of the patient until he or she received a drug regimen deemed appropriate for his or her DR. For patients with MDR or extreme-drug-resistant (XDR) tuberculosis, we considered a drug regimen "effective" if it included at least four drugs to which the patient's isolate was pan-susceptible. If a strain was resistant to at least one drug other than Rifampicin, we considered a regimen to be effective if it included at least three effective drugs, one of which was Rifampicin. If a strain was resistant to Rifampicin but not isoniazid or Pyrazinamide, we considered a regimen to be effective if it included at least three drugs to which strain was pan-susceptible, one of which was Pyrazinamide.
We categorized participants according to their alcohol intake as nondrinkers if they reported having consumed no alcoholic drinks per day), light drinkers if they reported drinking <40 grams or <3 alcoholic drinks per day and heavy drinkers if they reported drinking 40 grams of alcohol or more or 3 or more drinks per day. A large proportion of smokers reported smoking only a single cigarette per day. We classified people as nonsmokers if they reported no cigarette smoking, as light smokers if they reported smoking one cigarette per day and as heavy smokers if they reported smoking more than one cigarette per day. We defined nutritional status for children based on the World Health Organization body mass index (BMI) z-score tables. 3 We assigned people with BMI z-scores of less than 2 as underweight and those greater than 2 as overweight.
We created a continuous variable to capture summarize household-level socioeconomic status by including variables on housing quality, water supply and sanitation in a principal component analysis (PCA) (as described in 4.) PCA is a data reduction statistical technique that extracts a set of uncorrelated 'principal components' from a set of correlated variables, where each principal component is a weighted linear combination of the original variables. Appendix 2 provides the variables which were used to generate a composite social economic status (SES) score as a continuous variable and their weight in the first principal component. The continuous SES score was categorized into tertiles corresponding to relative "low," "middle," and "upper" SES.
Outcomes
Infection
We considered the following infection outcomes in our analyses: infection among household contacts at baseline, infection during 12 months of follow up among household contacts who were uninfected at baseline, and infection by 12 months of follow-up. We considered people infected at baseline if they had a history of prior tuberculosis disease, reported a history of a positive TST or had a positive TST at baseline. We considered people to have become infected with tuberculosis during follow up if they had a negative TST at baseline and a positive TST at some point during follow up.
Disease
We identified incident tuberculosis by direct household visits and from medical records from the hospitals within the study area. We considered household contacts to have coprevalent tuberculosis if they were diagnosed within two weeks of the diagnosis of the index case and to be "secondary" cases if they were diagnosed between days 15 and days 455 of follow-up (90 days extensive buffer time for the 12 months visit). Diagnosis of adult secondary tuberculosis followed the same criteria as outlined above for index cases. We assumed that we captured all incident cases, so all household contacts without evidence of progressive tuberculosis disease were considered disease-free at the end of follow-up. In addition, we defined secondary tuberculosis disease among contacts younger than 18 years of age according to the consensus guidelines for classifying tuberculosis disease in children. 5 
Data Analysis Infection at baseline and the end of follow-up
Because tuberculosis is a disease with an insidious onset, it is likely that many patients have had infectious tuberculosis for weeks or months prior to their presentation to a health facility for diagnosis. Thus, household contacts are likely to have been exposed to the index case during an infectious period of unknown duration and some of these will have become infected during this exposure prior to the time that the index case presents for diagnosis. Although we would expect that household contacts exposed to index cases who were more likely to transmit tuberculosis would have a higher prevalence of recent infection at the time of the diagnosis of the index case than those exposed to less infectious index cases, the tuberculin skin test does not distinguish between recent and more remote infection. An assessment of relative transmissibility of an index case that is based on the prevalence odds of Mycobacterium tuberculosis infection among the exposed and unexposed at baseline is therefore subject to bias by non-differential misclassification if a positive TST is taken as evidence of a recent transmission event. We have nonetheless chosen to report this estimate in addition to the risk of TST conversion from negative to positive conditional on the exposure because the TST negative population at the time of enrollment constitutes a "survival cohort" that may be depleted of those at highest risk for conversion. Thus, a very strong index patient risk factor for tuberculosis transmission might have led to earlier TST conversion, i.e., prior to the diagnosis of disease in the index case, and the population of household contacts with such an exposure who remain uninfected at baseline may include "infection resistors," people who experience "early clearance" of Mycobacterium tuberculosis infection and do not mount a cell mediated immune response that leads to TST conversion. 6 We estimated prevalence ratios for infection at baseline and by the end of follow-up using a modified Poisson generalized estimating equation to account for correlation among participants within a household. We specified an exchangeable working correlation structure for observations within the same household. For inference, we obtained empirical standard error estimates that were used to construct Wald type 95% confidence intervals. We first performed age-adjusted univariable analyses for covariates that were potential predictors of tuberculosis infection based on a priori background knowledge. Subsequently, all the covariates were entered into a backwards stepwise algorithm, with the exception of sputum smear status, length of symptomatic period, presence of cavitary disease, and time to effective treatment of index case, as we hypothesized that these risk factors may mediate the effects of the index patient's drug resistance status on the risk of tuberculosis infection among household contacts. We retained variables with p<0.1 and variables which were likely to modify Mycobacterium tuberculosis infection (HIV status of index case, smoking and drinking status of index case, and socioeconomic status of household) in the multivariable model. We also aimed to quantify the direct effect of drug-resistant profile on risk of tuberculosis transmission, i.e., the effect which was not mediated by smear status, duration of symptomatic disease, cavitation, or time to effective treatment of index case. We evaluated the direct effect by adding the mediators to the regression model, assuming that upon adjusting for the observed covariates, no unobserved confounding prevailed for the joint effects of the degree of the index patient's immunosuppression and these 4 mediators on the household contact's risk of tuberculosis infection. As noted above, this analytic approach implicitly assumes that all infected household contacts acquired infection from the index patient. If some household contacts acquired infection elsewhere, this would lead to non-differential misclassification of the exposure status and would be expected to attenuate our results toward the null. To address this, we conducted a sensitivity analysis restricting the analyzed cohort to children who we assumed were less likely to be infected in the past or in the community than adults.
Time to infection
We measured time from enrollment to infection among household contacts who were uninfected at baseline. We defined the date of infection as the midpoint between date of enrollment and the date of a positive TST result and we censored contacts who remained TST negative at the date of last TST result. We used a Cox frailty proportional hazards models to evaluate risk factors for incident Mycobacterium tuberculosis infection, accounting for clustering within households. In the multivariable model, we included variables identified a priori as potential confounders (HIV status of index case, smoking and drinking status of index case, and socioeconomic status of household) and any others associated with the outcome with a p value < 0.1 using a backwards stepwise algorithm. We verified the proportional hazards assumptions for each covariate by introducing an interaction term between the covariate and time; we stratified by variables for which the proportional hazards assumption did not hold. We followed the same logic described above evaluating the mediation effects of the four possible mediators, smear status, duration of symptomatic disease prior to diagnosis, cavitation on chest film, or time to effective treatment of index case. We repeated the sensitivity analysis described above restricting our analysis to child household contact based on the assumption that child contacts are more likely to be infected within household than adults.
Disease incidence
We measured the time from enrollment to disease occurrence among all household contacts except those with co-prevalent tuberculosis. We used a Kaplan-Meier curve to examine the disease-free survival time and Cox frailty proportional hazards models to evaluate risk factors for incident tuberculosis disease, accounting for clustering within households. In the multivariable model, we included variables identified a priori as potential confounders (HIV status of index case, smoking and drinking status of index case, socioeconomic status of household, and isoniazid preventive therapy) and any others associated with the outcome with a p value < 0.1 using a backwards stepwise algorithm. We followed the same logic described above evaluating the mediation effects of the four mediators. In a sensitivity analysis, we considered only those secondary patients who shared a MIRU pattern with the index case, excluding from the analysis those with secondary disease who did not share an index case. We conducted this sensitivity analysis in two different ways. In the first, we considered secondary cases whose 24 locus MIRU patterns were an exact match with the index case and in the second, we considered secondary cases whose MIRU patterns matched on 22 of 24 loci. Because the number of incident tuberculosis cases was low in these sensitivity analyses, we only performed the univariable analyses.
Results
In addition to the prevalence of infection by 12 months reported in the main text, we also assessed the prevalence odds of infection at baseline by drug-resistance profile both in the entire household contact cohort and in the subset of children younger than fifteen years Table S2 and S3 show that in both the entire cohort and among children, contacts exposed to patients with isoniazid mono-resistant or MDR tuberculosis were more likely to be infected at baseline. Other resistance phenotypes had no impact on the prevalence of infection at baseline. Point estimates for mono-isoniazid and MDR were further amplified in the subset of the cohort aged 15 and under.
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